EGFR and non-small cell lung carcinoma: Prior models have evaluated the cost-effectiveness of adjuvant osimertinib for individuals with EGFR-mutant resected NSCLC compared with placebo (Lemmon et al., 2022; Zhou et al., 2022; Verhoek et al., 2023).